Littérature scientifique sur le sujet « Yue feng xu jiu »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Yue feng xu jiu ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Yue feng xu jiu"
1
Xu, Jie, Fan Song, Baozhen Zhang, Huijue Lyu, Mikoto Kobayashi, Ziyu Zhao, Ye Hou et al. « Abstract 2953 : Subtype-specific and structure variation induced 3D genome alteration in acute myeloid leukemia ». Cancer Research 82, no 12_Supplement (15 juin 2022) : 2953. http://dx.doi.org/10.1158/1538-7445.am2022-2953.
Texte intégralRésumé :
Abstract Acute myeloid leukemia (AML) represents a set of heterogeneous myeloid malignancies hallmarked by mutations in epigenetic modifiers, transcription factors, and kinases that can cause epigenetic reshaping. It is unclear to what extent AML mutations drive chromatin 3D structure alteration and contribute to myeloid transformation. We first performed Hi-C and whole-genome sequencing in 25 AML patient samples and seven healthy donor samples, and identified recurrent alterations of A/B compartments, TADs, and chromatin loops that are unique to different subtypes. To investigate how altered chromatin organization contributes to transcriptional misregulation, we performed RNA-Seq, ATAC-Seq and CUT&ag for CTCF, H3K27ac, and H3K27me3 in the same AML samples. We identified extensive and recurrent AML-specific promoter-enhancer and promoter-repressor loops. We performed both CRISPR deletion and interference experiments and validated two repressor loops that downregulated cancer related genes IKZF2 and RTTN. Furthermore, by using our recently developed algorithm, we identified structural variation-induced enhancer-hijacking and repressor-hijacking events in AML samples. We further demonstrated the role of hijacked enhancers in AML cell growth by CRISPR screening, and the role of hijacked repressors by CRISPR de-repression. We performed whole-genome bisulfite sequencing in 20 AML and normal samples, and showed the delicate relationship between DNA methylation, CTCF binding and 3D genome structure. Finally, by treating the AML cells with the DNA hypomethylating agent and performing triple knockdown of DNMT1/3A/3B, we demonstrated the impact of altered DNA methylation on gene expression and 3D genome organization. Overall this study provides an invaluable resource for leukemia studies and also highlighted the role of repressor-loops and hijacked cis-elements in gene regulation and human diseases. Citation Format: Jie Xu, Fan Song, Baozhen Zhang, Huijue Lyu, Mikoto Kobayashi, Ziyu Zhao, Ye Hou, Xiaotao Wang, Yu Luan, Bei Jia, Lena Stasiak, Qixuan Wang, Qi Jin, Qiushi Jin, Yihao Fu, Ross C. Hardison, Sinisa Dovat, Leonidas C. Platanias, Yue Yang, Tomoko Yamada, Aaron D. Viny, Ross L. Levine, David F. Claxton, James R. Broach, Hong Zheng, Feng Yue. Subtype-specific and structure variation induced 3D genome alteration in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2953.
2
Zhao, Xiao Hong, Man Man Han, Qian Qian Yan, Yi Meng Yue, Kai Hong Ye, Yuan Yuan Zhang, Liu Teng et al. « Abstract 7052 : p53 underpins a dependence on oxidative phosphorylation in glycolysis-competent colorectal cancer ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 7052. http://dx.doi.org/10.1158/1538-7445.am2024-7052.
Texte intégralRésumé :
Abstract The use of mitochondrial inhibitors to target oxidative phosphorylation (OXPHOS) in cancer treatment presents a challenge due to dose-limiting toxicities. Moreover, while glycolysis-deficient cancers are vulnerable to OXPHOS inhibition in preclinical models, the full extent of phenotypical and mechanistic consequences of inhibiting OXPHOS in cancers capable of glycolysis is not yet well understood. Our results presented here offer promising insights into potential therapeutic gains from combining p53 restoration strategies with OXPHOS inhibitors, even when applied to glycolysis-competent CRC cells. Treatment with mitochondrial complex I inhibitors did not cause energy stress in CRC cells capable of glycolysis. It does, however, induce DNA replication stress, apparent through an observed cell cycle arrest at the S phase, enrichment of the G2/M DNA-damage checkpoint regulation pathway, and replication fork slowdown. Intriguingly, CRC cells harboring wildtype p53 exhibited more severe replication stress than those carrying mutant p53. Furthermore, siRNA knockdown of p53 attenuates replication stress and reduces cell cycle arrest, underlining the important role of p53 in CRC cell responses to OXPHOS inhibition. Our targeted metabolomics analysis reveals that OXPHOS inhibition results in reductions in the purine nucleotides, adenine monophosphate (AMP) and guanine monophosphate (GMP), as well as the pyrimidine nucleotide, uridine monophosphate (UMP), in CRC cells, regardless of their p53 mutational status. By supplementing cell culture mediums with the purine nucleobases adenine and guanine, and the pyrimidine nucleoside uridine, we observed a partial reversal of the replication fork slowdown and reductions in cell viability. This suggests nucleotide deficiencies are involved in the induction of DNA replication stress caused by OXPHOS inhibition. The nucleotide deficiencies were associated with a decrease in the nucleobase precursor aspartate. By adding aspartate at a supraphysiological concentration, to overcome the low expression of the excitatory amino acid transporter 1 required for cellular import of aspartate, we were able to restore the levels of nucleotides. Collectively, our findings suggest broader potential cancer treatment paradigms via OXPHOS targeting, extending beyond glycolysis-deficient cancers. Our data uncovers that CRC cells, which commonly exhibit the glycolytic phenotype, are susceptible to OXPHOS inhibition, with those carrying wildtype p53 showing heightened sensitivity. Therefore, p53 status could serve as a biomarker for predicting CRC responses to OXPHOS inhibitors. Moreover, our findings suggest that combined strategies of restoring p53 function, using small molecules such as APR-246, might enable reduced dosage of OXPHOS inhibitors in CRC treatment, thereby mitigating their dose-limiting toxicities. Citation Format: Xiao Hong Zhao, Man Man Han, Qian Qian Yan, Yi Meng Yue, Kai Hong Ye, Yuan Yuan Zhang, Liu Teng, Liang Xu, Xiao Jing Shi, Ting La, Yu Chen Feng, Ran Xu, Vinod K. Narayana, David P. De Souza, Tao Liu, Mark Baker, Rick F. Thorne, Xu Dong Zhang, Song Chen, Lei Jin. p53 underpins a dependence on oxidative phosphorylation in glycolysis-competent colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7052.
3
Whittingham, Stan, BEN PEI, Isik Buyuker, Krystal Lee, Fengxia Xin et Hui Zhou. « (Invited, Digital Presentation) Pushing the Limits of High Nickel NMC Cathodes ». ECS Meeting Abstracts MA2022-01, no 2 (7 juillet 2022) : 334. http://dx.doi.org/10.1149/ma2022-012334mtgabs.
Texte intégralRésumé :
Lithium-ion batteries now dominate electrochemical energy storage for vehicle propulsion and grid storage in addition to portable electronics. In 2022, they celebrate their 50th anniversary, and yet still achieve only 25% of their theoretical energy density. The dominant anode and cathode today are graphitic carbon and the layered NMC oxides, LI[NiMnCoAl]O2. Both need improving. Most of the carbon in the anode must go, and the NMCs need pushing to their limit and at the same time eliminating cobalt. I will today discuss the challenges faced as we push the limits of the NMCs to their limits, > 80% lithium cycling, and Ni>0.8 and Co <<0.1. The higher the Ni content the lower the charging voltage needed for a given cycling capacity, but the greater its surface and bulk reactivity. The issues discussed will include 1stcycle loss [1], high rate capability [2], cathode stability [3], and surface/bulk reactivity and the impact of surface/bulk modification [4,5] and the micron-size single crystals vs meatballs on these [6]. This work is being supported by DOE-EERE-BMR-Battery500 consortium. [1]. Hui Zhou, Fengxia Xin, Ben Pei, M. Stanley Whittingham, “What Limits the Capacity of Layered Oxide Cathodes in Lithium Batteries?”, ACS Energy Lett. 2019, 4: 1902−1906. [2]. Chunmei Ban, Zheng Li, Zhuangchun Wu, Melanie J. Kirkham, Le Chen, Yoon Seok Jung, E. Andrew Payzant, Yanfa Yan, M. Stanley Whittingham, and Anne C. Dillon “Extremely Durable High-Rate Capability of a LiNi0.4Mn0.4Co0.2O2 Cathode Enabled by Single–Wall Carbon Nanotubes”, Advanced Energy Materials, 2011, 1: 58-62. [3]. Hyung-Joo Noh, Sungjune Youn, Chong Seung Yoon, Yang-Kook Sun “Comparison of the structural and electrochemical properties of layered Li[NixCoyMnz]O2 (x = ¼ 1/3, 0.5, 0.6, 0.7, 0.8 and 0.85) cathode material for lithium-ion batteries”, J. Power Sources, 2013, 233: 121-130. [4]. Fengxia Xin, Hui Zhou, Yanxu Zong, Mateusz Zuba, Yan Chen, Natasha A. Chernova, Jianming Bai, Ben Pei, Anshika Goel, Jatinkumar Rana, Feng Wang, Ke An, Louis F. J. Piper, Guangwen Zhou, and M. Stanley Whittingham, “What is the Role of Nb in Nickel-Rich Layered Oxide Cathodes for Lithium-Ion Batteries?”, ACS Energy Letters, 2021, 6: 1377-1382. [5]. Ben Pei, Hui Zhou, Anshika Goel, Mateusz Zuba, Hao Liu, Fengxia Xin, and M. Stanley Whittingham, “Al Substitution for Mn during Co-Precipitation Boosts the Electrochemical Performance of LiNi0.8Mn0.1Co0.1O2”, J. Electrochemical Society, 2021, 68: 050532. [6]. Yujing Bi, Jinhui Tao, Yuqin Wu, Linze Li, Yaobin Xu, Enyuan Hu, Bingbin Wu, Jiangtao Hu, Chongmin Wang, JiGuang Zhang, Yue Qi and Jie Xiao, “Reversible planar gliding and microcracking in a single-crystalline Ni-rich cathode”, Science, 2020, 370: 1313-1317.
4
Newman, Ian M., Ling Qian, Niran Tamrakar, Yonghua Feng et Ganrong Xu. « Chemical content of unrecorded distilled alcohol (bai jiu) from rural central China : Analysis and public health risk ». International Journal of Alcohol and Drug Research 6, no 1 (4 octobre 2017) : 59–67. http://dx.doi.org/10.7895/ijadr.v6i1.236.
Texte intégralRésumé :
Newman, I., Qian, L., Tamrakar, N., Feng, Y., & Xu, G. (2017). Chemical content of unrecorded distilled alcohol (bai jiu) from rural central China: Analysis and public health risk. The International Journal Of Alcohol And Drug Research, 6(1), 59-67. doi:http://dx.doi.org/10.7895/ijadr.v6i1.236Aims: To test 47 samples of locally distilled unrecorded beverage alcohol (bai jiu) obtained in rural central China.Methods: Alcohol samples purchased from home-based makers or from small village shops were analyzed for ethanol, methanol, acetaldehyde, ethyl acetate, six higher alcohols, arsenic, cadmium, and lead. Results were judged against the standards for these compounds set by the AMPHORA Project.Findings: Ethanol concentrations ranged from 38.7% to 63.7% (mean 50.4%). Methanol and methyl acetate detected in all samples did not exceed the Alcohol Measures for Public Health Research Alliance (AMPHORA) limits. Acetaldehyde was present in all samples, with three samples exceeding the AMPHORA limit by a small amount. Lead was found in 57.4% of the samples with one sample exceeding the AMPHORA limit; cadmium was found in 89.4% of the samples with two exceeding the AMPHORA limit. Arsenic was found in 46.8% of the samples with none exceeding the AMPHORA limit.Conclusions: The three samples that exceeded AMPHORA limits for cadmium or lead are of concern in terms of the potential of long-term exposure for local people who regularly consume locally made bai jiu. The main health concern from bai jiu appears to be the risk associated with high ethanol concentration—the same health concern as for recorded, commercially produced spirits.
5
Newman, Ian M., Ling Qian, Niran Tamrakar, Yonghua Feng et Ganrong Xu. « Chemical content of unrecorded distilled alcohol (bai jiu) from rural central China : Analysis and public health risk ». International Journal of Alcohol and Drug Research 6, no 1 (4 octobre 2017) : 59–67. http://dx.doi.org/10.7895/ijadr.v0i0.236.
Texte intégralRésumé :
Newman, I., Qian, L., Tamrakar, N., Feng, Y., & Xu, G. (2017). Chemical content of unrecorded distilled alcohol (bai jiu) from rural central China: Analysis and public health risk. The International Journal Of Alcohol And Drug Research, 6(1), 59-67. doi:http://dx.doi.org/10.7895/ijadr.v6i1.236Aims: To test 47 samples of locally distilled unrecorded beverage alcohol (bai jiu) obtained in rural central China.Methods: Alcohol samples purchased from home-based makers or from small village shops were analyzed for ethanol, methanol, acetaldehyde, ethyl acetate, six higher alcohols, arsenic, cadmium, and lead. Results were judged against the standards for these compounds set by the AMPHORA Project.Findings: Ethanol concentrations ranged from 38.7% to 63.7% (mean 50.4%). Methanol and methyl acetate detected in all samples did not exceed the Alcohol Measures for Public Health Research Alliance (AMPHORA) limits. Acetaldehyde was present in all samples, with three samples exceeding the AMPHORA limit by a small amount. Lead was found in 57.4% of the samples with one sample exceeding the AMPHORA limit; cadmium was found in 89.4% of the samples with two exceeding the AMPHORA limit. Arsenic was found in 46.8% of the samples with none exceeding the AMPHORA limit.Conclusions: The three samples that exceeded AMPHORA limits for cadmium or lead are of concern in terms of the potential of long-term exposure for local people who regularly consume locally made bai jiu. The main health concern from bai jiu appears to be the risk associated with high ethanol concentration—the same health concern as for recorded, commercially produced spirits.
6
Teixeira Gama, Benedita. « Critical Review : Restructuring Translation Education : Implications from China for the Rest of the World, by Feng Yue, Youlan¬ Tao, Huashu Wang, Qiliang Cui¬ and Bin Xu ». Belas Infiéis 10, no 2 (9 décembre 2021) : 01–07. http://dx.doi.org/10.26512/belasinfieis.v10.n2.2021.33860.
Texte intégralRésumé :
Este trabalho trata dos problemas da educação em tradução no contexto de localização e a globalização na era do big data, destacando as importantes mudanças no mercado de tradução e apontando as insuficiências nas propostas de ensino, desenho de currículo e desenvolvimento do corpo docente na graduação da China e nos programas de pós-graduação em tradução. É discutido, ainda, as soluções que foram experimentadas com sucesso na Universidade Normal de Shandong, Shanghai Foreign Languages University, Universidade de Zhejiang, Universidade da China de Petróleo, Universidade Normal de Fujian, Universidade Nankai e Universidade Fudan, que podem ser adaptadas às situações de outras faculdades e universidades.
7
Wang, Xue, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Xiaochen Zhao, Binghe Xu et Peng Yuan. « Abstract 5084 : KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer ». Cancer Research 82, no 12_Supplement (15 juin 2022) : 5084. http://dx.doi.org/10.1158/1538-7445.am2022-5084.
Texte intégralRésumé :
Abstract Background: Chemotherapy is the most common treatment strategy for triple negative breast cancer (TNBC) patients. Nevertheless, due to adverse drug reactionsthe molecular high heterogeneity of TNBC and no appropriate meaningful efficacy markers, it is still difficult to establish preferred therapeutic strategies and predict the outcomes for TNBC. This study was to investigate the potential predictors and therapeutic targets based on genetic features. Methods: A total of 386 TNBC patients were randomized 1:1 to receive either six cycles of paclitaxel + cisplatin (TP) or four cycles of epirubicin + cyclophosphamide followed by four cycles of docetaxel (EC-T) adjuvant chemotherapy after surgery (NCT01150513), which were described previously. Finally, 149 TNBC patients with clinical and tumor sequencing data availability were retrospectively analysed by NGS for 733 cancer-related genes. All tumor samples were collected during the surgical operation and subjected to NGS for evaluating genomic mutations and the potential predictors. Cox regression model and Kaplan-Meier method were applied to evaluate disease-free survival (DFS). Results: In the surgical cohort receiving adjuvant chemotherapy, 74 patients received platinum and 75 received platinum-free chemotherapy as adjuvant chemotherapy. The most frequently mutated genes in this surgical TNBC cohort were TP53 (84%), BRCA1 (18%), BRCA2 (15%), POL1 (13%), PTEN (12%), REV3L (11%), FANCC (10%), and PARP4 (10%). We analyzed the associations between 733 cancer-related gene mutations and DFS after adjuvant chemotherapy. For the TP group, PIK3CA mutation (19%, 14/74) was discovered to correlate with poor DFS for patients treated with platinum-containing adjuvant therapy (HR=3.2, P=0.037), and KMT2D mutation (15%, 11/75) display worse DFS for patients treated with EC-T platinum-free group (HR=3.0, p=0.039). However, BRCA1/2 mutation (24%, 35/149) was found to be associated with poor prognosis (HR=2.1 (95% CI: 1-4.6), p=0.047), irrespective of therapeutic regimen. Conclusions: In this population of surgical TNBC patients, NGS analysis identified potential predictive markers. PIK3CA mutation in TP platinum-containing group and KMT2D mutation in EC-T platinum-free group were significantly associated to poor prognosis for adjuvant chemotherapy in triple negative breast cancer. Citation Format: Xue Wang, Feng Du, Jian Yue, Yiran Si, Lina Cui, Bei Zhang, Xiaochen Zhao, Binghe Xu, Peng Yuan. KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5084.
8
Beltran, Pedro, Simanshu Dhirendra, Rui Xu, Ming Chen, Daniel Czyzyk, Sofia Donovan, Siyu Feng et al. « Abstract RF02-02 : BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism ». Cancer Research 84, no 9_Supplement (2 mai 2024) : RF02–02—RF02–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-rf02-02.
Texte intégralRésumé :
Abstract PI3Kα is the most mutated kinase and the second most mutated oncogene in human cancer. Activation of PI3Ka can be achieved by receptor tyrosine kinases such as insulin receptor and insulin-like growth factor receptor 1 and/or by directly interacting with RAS family members. Previous elegant preclinical studies have established that RAS-driven PI3Ka activation is important in tumor cells but may not be involved in cell types controlling glucose metabolism. Alpelisib, a small molecule inhibitor of the kinase activity of PI3Ka, has been approved for the treatment of ER+ PIK3CA mutant breast cancer in combination with fulvestrant after endocrine therapy in advanced or metastatic breast cancer based on an improvement in PFS versus fulvestrant alone. Inhibition of PI3Ka activity by alpelisib in normal tissues resulted in a severe (G3/4) hyperglycemia rate of 37% with frequent dose interruptions and discontinuations. Additionally, preclinical studies have demonstrated that the dysregulation of glucose homeostasis resulting from PI3Ka kinase inhibition leads to hyperinsulinemia that increases pathway flux, rendering kinase inhibitors less effective. Here, we report on a novel covalent small molecule designed to inhibit RAS-mediated activation of the AKT pathway via PI3Ka without the resultant hyperglycemia associated with direct inhibition of PI3Ka kinase activity. BBO-10203 disrupts the physical interaction between RAS and PI3Ka in tumor cells resulting in potent signaling pathway inhibition. This agent selectively binds to PI3Ka and disrupts its interaction with K-,H-, and N-RAS with low single digit nanomolar potency (~5 nM). Breaking the interaction between these two oncogenes inhibits basal pAKT cellular levels (BT-474/KYSE-410 IC50: ~5 nM) in HER2 amplified (HER2amp) and wild-type or mutant PI3Ka cell lines. Even though BBO-10203 does not inhibit the kinase activity of PI3Ka, its effects on cancer cell signaling inhibition and transcriptional regulation highly resemble those of alpelisib. BBO-10203 displays excellent drug-like properties and oral bioavailability. Single dose treatment of KYSE-410 (HER2amp/KRASG12C) tumor bearing mice with increasing doses (1-100 mg/kg, PO) of BBO-10203 results in dose and time dependent inhibition of pAKT in vivo. Maximal inhibition (~80%) is achieved at 30 mg/kg and lasts for 24 hours. Repeated dose treatment of tumor bearing mice with BBO-10203 is well tolerated and results in significant efficacy in PIK3CA mutant as well as HER2amp human xenograft models. In the KYSE-410 xenograft model, BBO-10203 daily oral dosing of 30 mg/kg results in significant tumor regressions. Importantly, treatment with BBO-10203 does not affect insulin signaling in differentiated adipocytes in vitro, nor does it impact glucose metabolism in vivo at 3-times the maximal efficacious dose level in xenograft studies. In conclusion, we have identified a novel approach to inhibit the PI3Ka signaling pathway by blocking its interaction with, and activation by RAS. This approach can achieve strong pAKT inhibition in tumor cells without changes in glucose metabolism. Clinical investigation of BBO-10203 for the treatment of both ER+/PIK3CA mutant and HER2amp breast cancer is warranted. Citation Format: Pedro Beltran, Simanshu Dhirendra, Rui Xu, Ming Chen, Daniel Czyzyk, Sofia Donovan, Siyu Feng, Cindy Feng, Lijuan Fu, Felice Lightstone, Ken Lin, Anna Maciag, Dwight Nissley, Erin Riegler, Kerstin Sinkevicius, Andrew Stephen, James Stice, David Turner, Bin Wang, Keshi Wang, Yue Yang, Cathy Zhang, Frank McCormick, Eli Wallace. BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr RF02-02.
9
Li, Qiao, Qingyuan Zhang, Yue Zhang, Quchang Ouyang, Qiang Liu, Tao Sun, Feng Ye et al. « Abstract PD11-10 : PD11-10 Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trial ». Cancer Research 83, no 5_Supplement (1 mars 2023) : PD11–10—PD11–10. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd11-10.
Texte intégralRésumé :
Abstract Background: Despite recent FDA approval of immune checkpoint inhibitor pembrolizumab and drug-antibody conjugate in the treatment of mTNBC, the overall survival benefit of these patients remains modest. We conducted a phase 2 study to assess the efficacy and safety of anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in mTNBC patients (pts) regardless of PD-L1 status. Preliminary results have been delivered in 2021 AACR[1], here we reported the final results of the progression-free survival (PFS) and overall survival (OS) analysis. Methods: This study enrolled pts with treatment-naïve locally advanced inoperable or metastatic TNBC. Eligible pts received nab-paclitaxel plus KN046 at two dose levels (DL1: KN046 3 mg/kg Q2W or DL2: KN046 5 mg/kg Q2W). Tumor response was evaluated Q8W per RECIST 1.1. The primary endpoint included objective response (ORR) and duration of response (DoR), secondary included disease control rate (DCR), clinical benefit rate (CBR), PFS, 1-year/2-year OS rate and safety/tolerability. Results: As of May 9, 2022 (cut-off date), 27 pts were enrolled into DL1 (n=16) and DL2 (n=11). Median patient age in the study was 50 years (range, 33-70 years). At baseline, 52% and 48% of patients had ECOG PS of 0 and 1, respectively. By the cut-off date, there are 1 pts under treatment and 16pts alive. The median study follow-up time was 26.3 months (95% CI, 20.7 - 29.8). Based on the intent-to-treatment (ITT) population, the confirmed ORR was 33.3% (95% CI, 16.5% - 54.0%), DCR was 88.9% (95% CI, 70.8% - 97.7%), and CBR was 48.1% (95% CI, 28.7% - 68.1%), which remained stable compared with last reported in 2021 [1]. The DoR was 11.9 (95% CI, 5.6 - NR) months. The median PFS was 7.3 (95% CI, 3.7 - 13.7) months. The median OS is immature, the preliminary result is 27.7 (95% CI, 14.8 - NR) months, and the 2-year OS rate was 60.1% (95%CI, 37.2% - 76.9%). Among the 11 pts with PD-L1 positive (≥1% IC), confirmed ORR was 45.5% (95%CI, 16.7% - 76.6%) and mPFS was 8.61 (95%CI, 1.6 - 13.8) months. Both PD-L1 positive and negative pts derived OS benefit from the combination treatment, with the 2-year OS rate of 57.14% (95%CI, 25.4% - 79.6%) and 62.5% (95%CI, 22.9% - 86.1%) respectively. Patients tolerated well to combination therapy in this trial. The most common reported treatment related adverse event (TRAEs) were ALT elevation (13 pts, 48%), AST elevation (12 pts, 44%), pyrexia (9 pts, 33%), neutropenia (8 pts, 30%), and anemia (7 pts, 26%). Grade ≥3 TRAEs (≥10%) were neutropenia (7 pts, 26%), leukopenia (6 pts, 22%) and AST elevation (5 pts, 15%). 13 pts (48%) experienced immune related adverse events (irAEs), and only 3 irAEs (11%) were grade 3. The incidence of SAE was 33%, with no TRAE leading to death. Conclusions: The combination therapy of KN046 plus nab-paclitaxel has shown favorable clinical efficacy in mTNBC, especially in PD-L1 positive patients. By the cut-off date, the mOS is not mature and there is still more than half of pts alive, which demonstrated an encouraging 2-year OS rate. Pts in this trial tolerated well to the combination therapy and safety profile was manageable. Clinical trial information: NCT03872791 Reference 1. Cancer Res (2021) 81 (13_Supplement): 1660. Citation Format: Qiao Li, Qingyuan Zhang, Yue Zhang, Quchang Ouyang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Ting Xu, Summer Xia, Karl Zhang, Bangyong Zhang, Binghe Xu. PD11-10 Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD11-10.
10
Kochanowicz, Marcin, et Jakub Markiewicz. « Broadband near-infrared emission in barium gallo-germanate glasses co-doped with bismuth, chromium and erbium ions ». Photonics Letters of Poland 16, no 1 (2 avril 2024) : 1–3. http://dx.doi.org/10.4302/plp.v16i1.1247.
Texte intégralRésumé :
This work presents barium gallo-germanate glasses co-doped with Bi+/Er3+ and Cr3+/Er3+ ions for NIR luminescence. The addition of Al2O3 content in the glass matrix made it possible to obtain luminescence corresponding to the 3P1→3P0 transition of Bi+ ions. Co-doping with the Bi+/Er3+ system resulted in a broad luminescence spectrum of 1.0-1.6 µm and Cr3+/Er3+ co-doping in selected glass matrix resulted in luminescence in 0.9-1.6 µm band. However, the luminescence of the Cr3+ ions is much lower than that of Er3+ ions. Full Text: PDF References T. Suzuki, G.S. Murugan, and Y. Ohishi, 'Optical properties of transparent Li2O-Ga2O3-SiO2 glass-ceramics embedding Ni-doped nanocrystals', Appl. Phys. Lett., 86(13), 131903 (2005). CrossRef N.V. Golubev et al., 'Pre-crystallization heat treatment and infrared luminescence enhancement in Ni2+-doped transparent glass-ceramics', J. Non-Cryst. Solids, 515, 42 (2019) CrossRef Z. Xu, W. Feng, T. Chen, X. Liu, and J. Qiu, 'Tuning optical properties in PbSe quantum dot-doped borosilicate glass fiber by modulation of network topology', Opt. Laser Technol., 158, 108910 (2023). CrossRef M.A. Hughes, T. Suzuki, and Y. Ohishi, 'Spectroscopy of bismuth-doped lead-aluminum-germanate glass and yttrium-aluminum-silicate glass', J. Non-Cryst. Solids, 356(44), 2302 (2010). CrossRef J. Song, Z. Zhou, B. Zhong, M. Zhang, J. Huang, and L. Han, 'Ultra-broadband near-infrared Cr3+-doped multi-phase glass-ceramics realized by the selective enrichment strategy for near-infrared spectroscopy applications', J. Alloys Compd., 968, 172126 (2023). CrossRef M.A.U. Martines, M.R. Davolos, M.J. Júnior, D.F. de Souza, and L.A.O. Nunes, 'Cr3+ and Cr4+ luminescence in glass ceramic silica', J. Lumin., 128(11), 1787 (2008). CrossRef S. Zhou, H. Dong, H. Zeng, J. Hao, J. Chen, and J. Qiu, 'Infrared luminescence and amplification properties of Bi-doped GeO2−Ga2O3−Al2O3 glasses', J. Appl. Phys., 103(10), 103532 (2008). CrossRef T. Suzuki and Y. Ohishi, 'Ultrabroadband near-infrared emission from Bi-doped Li2O-Al2O3-SiO2 glass', Appl. Phys. Lett., 88(19), 191912 (2006). CrossRef T. Minh Hau et al., 'Super broadband near-infrared emission and energy transfer in Bi-Er co-doped lanthanum aluminosilicate glasses', Opt. Mater., 35(3), 487 (2013). CrossRef H.K. Dan et al., 'Effects of Y3+on the enhancement NIR emission of Bi+-Er3+ co-doped in transparent silicate glass-ceramics for Erbium-doped fiber amplifier (EDFA)', J. Lumin., 219, 116942 (2020). CrossRef E.M. Dianov, 'Bismuth-doped optical fibers: a challenging active medium for near-IR lasers and optical amplifiers', Light Sci. Appl., 1(5) (2012). CrossRef L. Wang, L. Tan, Y. Yue, M. Peng, and J. Qiu, 'Efficient Enhancement of Bismuth NIR Luminescence by Aluminum and Its Mechanism in Bismuth‐Doped Germanate Laser Glass', J. Am. Ceram. Soc., 99(6), 2071 (2016). CrossRef Z. Jiang et al., 'Effects of Al2O3 composition on the near-infrared emission in Bi-doped and Yb-Bi-codoped silicate glasses for broadband optical amplification', J. Non-Cryst. Solids, 383, 196 (2014). CrossRef
Thèses sur le sujet "Yue feng xu jiu"
1
Ho, Fung-man. « Historical, mythological and literary allusions in Li Bai's Gufeng and Yuefu poems Li Bai gu feng ji yue fu shi dian gu tan jiu / ». Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40676511.
Texte intégral
2
CHUNG, SHAO-CHEN, et 鍾韶真. « Ming Tulong Ji Feng Yi Ge Yue Fu Pai Chang YiShu Yan Jiu ». Thesis, 2015. http://ndltd.ncl.edu.tw/handle/d2jtf5.
Texte intégralRésumé :
碩士東吳大學
中國文學系
103
Tulong (1543-1606), once had another name Changqing, Wei-Zhen , and Chi-Shui. Who was bone in Ningbo Yinxian。He was a famous writer and drmatist. This research which range was all Tulong’s life, his friends about drama and his works " feng- yi-ge-yue-fu". This research used Geographic Information System（GIS）and pai-chang theory, to discuss Tulong’s influence about drama in late ming dynasty. The first chapter discussed all Tulong’s life, and background which about late ming dynasty. The first chapter referenced Xu Shuo Fang’s "Wan Ming Qu Jia Nian Pu" and Wang Chao Hong’s "Ming Qing Zhe Ji Qu Jia Kao" to study period, location, dating events, friends, and works……exc fourteen project. Tulong’s life had tow very important things which is “zhong ju ren guan” and “ba guan gui xiang”. These Thing divided all Tulong’s life into three parts. This chapter will draw painting to discuss.At last it will research the location which about Tulong’s drama and fridnds to discuss Tulong’s influences in drama. The second chapter is about Tulong’s script . Tulong creared three scripts which is “tan hua ji”, “cai hao ji ”and “xiu wen ji”. Three scripts was named “ feng- yi-ge-yue-fu”. This chaper introduced story what time was creared about three scripts, theme, and version. This chapter introduced plot, architecture and character image in three scripts at last. The third chapter is about “tan hua ji” pai chang artistic research. It introduced pai chang theory in the first. The theory was according to luo li rong “Qu Xue Gai Yao”. This theory is on the basis of this research. This chapter arranged character in each parts, and discussed form , characteristic, and pai chang leng re whichis according to pai chang theory. This chapter analysised character ‘s work and reset by character appearances and songs. This chapter is to discuss “tan hua ji” achievements in drama. The fourth chapter is about “cai hao ji ” pai chang art. It discussed pai chang leng re by counting character’s appearance, form and characteristic in each parts. It discussed analysised character ‘s work and reset by character appearances and songs. The fifth chapter is about “cai hao ji ” pai chang art. It discussed pai chang leng re by counting character’s appearance, form and characteristic in each parts. It discussed analysised character ‘s work and reset by character appearances and songs. Conclusion part summarizes the TuLong and location. It discussed all Tulong’s life has been to place, and friends about drama, and influences in drama. It discussed “Qu Xue Gai Yao” pai chang achienement in drama.
Livres sur le sujet "Yue feng xu jiu"
1
Xu Xinliu ji jin hui. Xu Xinliu : Minguo jin rong chuan qi ren wu : Shen mei he yue yi men feng ya. [China] : [Xu Xinliu ji jin hui chu pin], 2014.
Trouver le texte intégral
2
Da Tang feng yue xu Xu xian fei. Chongqing : Chongqing chu ban she, 2009.
Trouver le texte intégral
3
Li, Gang. Feng kuang Java jiang yi. 8e éd. Beijing : Dian zi gong ye chu ban she, 2014.
Trouver le texte intégral
4
Li, An. Yue Fei shi shi yan jiu xu ji. 8e éd. Taibei Shi : Taiwan Shang wu yin shu guan, 1987.
Trouver le texte intégral
5
An, Li. Yue Fei shi shi yan jiu xu ji. 8e éd. Taibei Shi : Taiwan shang wu yin shu guan, 1987.
Trouver le texte intégral
6
An, Li, dir. Yue Fei shi shi yan jiu xu ji. Taibei Shi : Taiwan shang wu yin shu guan, 1987.
Trouver le texte intégral
7
man, Cha pu. R yu yan shi chang yan jiu fen xi = : R for marketing research and analytics. Beijing : Ji xie gong ye chu ban she, 2016.
Trouver le texte intégral
8
Yi, Wang Gang, et Yang Jufeng Yi, dir. C++ cheng xu she ji yu yan : Di 1~3 bu fen = The C++ programming language. Beijing : Ji xie gong ye chu ban she, 2016.
Trouver le texte intégral
9
Sahni, Sartaj. Shu ju jie gou, Suan fa yu ying yong : C++ yu yan miao shu = Data structures, algorithms, and applications in C++. Beijing : Ji xie gong ye chu ban she, 2015.
Trouver le texte intégral
10
Guang dong sheng dian li gong ye zhi ye ji shu xue xiao, dir. An quan sheng chan guan li zhi du yu an feng ti xi. Beijing : Zhong guo dian li chu ban she, 2015.
Trouver le texte intégral